Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Kent Reifschneider

Pediatric Endocrinology Norfolk, VA Medical Doctor

NPI 1619184710 CMS profile 209175

601 Childrens Ln, Norfolk, VA 23507

Open in the dashboard

General payments

$133,154

287 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$63,060 paid to institutions, not to them · program years 2022–2023

Through program year 2023, Kent Reifschneider of Norfolk, VA is reported in the CMS Open Payments database as having received $133,154 across 287 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $63,060 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $57,034 133
2022 General $38,730 96
2021 General $6,190 4
2020 General $25,580 33
2019 General $5,621 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kent Reifschneider
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Kent Reifschneider were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Kent Reifschneider Pediatric Endocrinology median Middle half National median
2019 $5,621 $196 $68–$845 $163
2020 $25,580 $124 $37–$722 $114
2021 $6,190 $134 $35–$691 $132
2022 $38,730 $177 $47–$726 $149
2023 $57,034 $236 $75–$887 $160
2024 $0 $259 $91–$979 $164
2025 $0 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Ascendis Pharma, Inc. $89,494 202 payments
  2. AbbVie, Inc. $18,545 22 payments
  3. Medtronic MiniMed, Inc. $7,096 15 payments
  4. Endo Pharmaceuticals Inc. $6,416 17 payments
  5. Sandoz Inc. $4,149 1 payment
  6. Novo Nordisk Inc $3,084 10 payments
  7. Medtronic, Inc. $1,966 2 payments
  8. VistaPharm, Inc. $1,540 1 payment
  9. Ultragenyx Pharmaceutical Inc. $319 4 payments
  10. BioMarin Pharmaceutical Inc. $155 2 payments
  11. Other $390 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $81,865 45 payments
  2. Consulting Fee $25,884 12 payments
  3. Travel and Lodging $20,564 128 payments
  4. Food and Beverage $4,557 94 payments
  5. Education $283 8 payments
Products named General payments · program years 2019–2023
  1. SKYTROFA $89,494 202 payments
  2. LUPRON DEPOT Endocrinology $10,158 11 payments
  3. LUPRON DEPOT Endocrinology $8,387 11 payments
  4. SUPPRELIN $6,416 17 payments
  5. Norditropin $2,720 2 payments
  6. Thyquidity $1,540 1 payment
  7. Minimed 670G System $1,241 9 payments
  8. Sogroya $161 5 payments
  9. Cryvista $142 2 payments
  10. VOXZOGO $124 1 payment
  11. Other $404 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record